TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company

Transcenta, Biologics, Antibody, Claudin 18.2

TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company

Careers Contact
Scientific Publications

TST001 in Combination with Nivolumab plus Capecitabine and Oxaliplatin as First-line or with Nivolumab as Late-line Treatment in locally Advanced and Metastatic Gastric/Gastroesophageal Junction (G/GEJ) Cancer: Design of Cohorts from a Phase I/IIa Study

18 Jan, 2023


Weijian Guo1, Jifang Gong3, Caroline Germa2, Chuan Qi2, Chunhua Qian2, Jenny Yao2, Jianming Wang2, Li Xu2,Lijuan Zhang2, Xueming Qian2, Zhenzhong Xia2, Lin Shen3

  1. Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China;

  2. Suzhou Transcenta Therapeutics Co., Ltd.,

  3.  Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China


  • Gastric cancer (GC) remained the 4th leading cause of cancer death worldwide, accounting for about 7.7% of all cancer related mortality1.

  • Combinations of platinum and fluoropyrimidine are the preferred first-line chemotherapy regimen for patients with HER2 negative advanced gastric cancer2. Recently, Nivolumab was approved in combination with chemotherapy for first-line treatment of patients with advanced or metastatic gastric cancer. Though treatment outcome being improved, the median overall survival of nivolumab plus chemotherapy was still less than 14 months3.

  • Claudin-18 isoform 2 (CLDN18.2) is a member of the human claudin family of tetraspan membrane proteins that are crucial structural and functional components of tight junctions4. Unlike other family members, CLDN18.2 expression is strictly limited to differentiated epithelial cells of gastric mucosa4, 5. Interestingly CLDN18.2 is ectopically expressed at a significant level in multiple tumor types including gastric, esophageal, pancreatic and lung cancers, making it an attractive anti-cancer target5. In G/GEJ cancer, its expression is independent from PD-L16.

Trial Status:

  • As of Dec 20, 2022, 7 subjects in Cohort G and 3 in Cohort H have been enrolled. The enrollment is ongoing.